What is the recommended intravenous dosing regimen for caspofungin (echinocandin antifungal) in adults, including dose adjustments for hepatic impairment, and in pediatric patients?

Caspofungin Dosing Regimen

For adults, administer caspofungin as a 70-mg IV loading dose on Day 1, followed by 50 mg once daily thereafter, infused over approximately 1 hour. 1

Adult Dosing by Indication

Standard Dosing (≥18 years)

• Loading dose: 70 mg IV on Day 1
• Maintenance dose: 50 mg IV once daily
• Administration: Slow IV infusion over approximately 1 hour (never as bolus) 1

Dose escalation: If the 50-mg dose is well tolerated but provides inadequate clinical response, increase to 70 mg daily 2, 1

Duration by Indication

• Candidemia/invasive candidiasis: Continue for at least 14 days after last positive culture 2, 1
• Esophageal candidiasis: 50 mg daily for 7-14 days after symptom resolution (no loading dose studied for this indication) 2, 1
• Invasive aspergillosis: Based on disease severity, immunosuppression recovery, and clinical response 1
• Empirical therapy in febrile neutropenia: Until neutropenia resolution; minimum 14 days after last positive culture if fungal infection confirmed 2, 1

Pediatric Dosing (3 months to 17 years)

Administer 70 mg/m² IV loading dose on Day 1, followed by 50 mg/m² once daily (maximum 70 mg regardless of calculated dose). 1

Calculation Method

• Calculate body surface area (BSA) using Mosteller Formula
• Loading dose (mg) = BSA (m²) × 70 mg/m²
• Maintenance dose (mg) = BSA (m²) × 50 mg/m²
• Maximum dose: 70 mg (both loading and maintenance) 1

Dose escalation: If 50 mg/m² daily is well tolerated but inadequate, increase to 70 mg/m² daily (not exceeding 70 mg absolute dose) 1, 3

Important caveat: Data in neonates <3 months are insufficient to establish safe/effective dosing. Neonatal candidiasis has higher CNS involvement rates, and caspofungin's blood-brain barrier penetration is unknown. Not studied for pediatric endocarditis, osteomyelitis, or meningitis due to Candida 1

Hepatic Impairment Adjustments

Adults

• Mild impairment (Child-Pugh 5-6): No adjustment needed 1
• Moderate impairment (Child-Pugh 7-9):
  • Loading dose: 70 mg on Day 1 (where appropriate)
  • Maintenance: 35 mg once daily 1, 4
• Severe impairment (Child-Pugh >9): No clinical experience; use with extreme caution 1

Critical evidence conflict: Recent research 5 challenges the FDA recommendation, showing that dose reduction to 35 mg in cirrhotic patients results in lower drug exposure than standard dosing in non-cirrhotic patients, potentially causing subtherapeutic levels. However, the FDA label recommendation should be followed in clinical practice until official guidance changes, particularly given the established safety profile at reduced doses 1.

Pediatrics

No clinical experience in pediatric patients with any degree of hepatic impairment 1

Drug Interaction Adjustments

Adults on CYP Inducers

• Rifampin: Increase to 70 mg once daily 1
• Other inducers (efavirenz, nevirapine, carbamazepine, dexamethasone, phenytoin): Consider 70 mg once daily 1

Pediatrics on CYP Inducers

• Rifampin or other inducers: Increase to 70 mg/m² once daily (not exceeding 70 mg) 1
• Important: Dexamethasone reduced trough concentrations by 44% in limited pediatric data (n=4) 3

Special Populations

Renal Impairment

No dose adjustment necessary for any degree of renal impairment. Caspofungin is not dialyzable; no supplementary dosing needed after hemodialysis 1

Elderly (≥65 years)

No dose adjustment recommended, though plasma concentrations may increase approximately 28% compared to younger adults 1

Therapeutic Drug Monitoring Considerations

Consider TDM-guided dosing in high-risk populations 6, 7:

• Premature neonates
• Critically ill patients with altered volume of distribution
• Patients on extracorporeal circuits
• Severe hypoalbuminemia
• Morbidly obese patients
• Treatment failure cases

Target trough: Cmin >1 mg/L provides acceptable exposure based on current MIC distributions 6, 7

Common Pitfalls to Avoid

1. Never administer as IV bolus - must be infused over approximately 1 hour 1
2. Don't forget the loading dose - except for esophageal candidiasis where it hasn't been studied 1
3. Don't underdose obese patients - standard dosing applies; consider TDM 6, 7
4. Monitor for hepatobiliary adverse reactions in pediatric patients with serious underlying conditions 1
5. Don't assume adequate CNS penetration - not established for meningitis or CNS candidiasis 1